ABSTRACT
Objective:To investigate the medical ethics and willingness to participate in pharmacological clinical trials of patients with chronic diseases, and explore the related factors. Methods:In December, 2020, 318 patients with chronic diseases from the Department of Internal Medicine, Beijing Bo'ai Hospital were investigated with a self-made medical ethics questionnaire for the items of medical ethics and willingness to participate in pharmacological clinical trials. Results:The attention to medical knowledge, awareness of their rights and responsibilities were various with the courses of disease, educational levels and resident areas. The satisfaction for treatment and trust to the doctors were related with the willingness to participate in pharmacological clinical trials by multivariate Logistic regression (P < 0.05). The patients in trials paid the most attention to the safety of the trail, and then the therapeutic effect. Conclusion:Promoting and protecting the medical rights, improving the trust to doctors, strengthening the publicity of clinical trial knowledge, may promote the willingness to participate in pharmacological clinical trials of patients with chronic diseases.
ABSTRACT
Objective:To observe the condition of obesity and dietary nutrition for stroke patients accepting rehabilitation. Methods:From November, 2015 to June, 2018, 115 inpatients were investigated their height, body mass, somatotype and dietary. They were divided into 18-49 year-old group (n = 41), 50-64 year-old group (n = 54) and ≥ 65 year-old group (n = 20). Results:The ratio of overweight/obesity and abdominal obesity were high in all the groups. There were significant differences in the overweight/obesity ratio among the three groups (χ2 = 6.978, P < 0.05), but not in abdominal obesity ratio (χ2 = 3.290, P > 0.05). Their intake of energy, carbohydrate, vitamin B1, vitamin B2, vitamin E, calcium, potassium, magnesium and selenium in all the groups was less than the recommendation (t > 2.548, P < 0.05), while the intake of cholesterol, iron, phosphorus and copper was more (t > 2.476, P < 0.05). The intake of protein and fat was more than the recommendation in the 18-49 year-old and the 50-64 year-old groups (t > 2.041, P < 0.05), and the intake of niacin was more than the recommendation in the 18-49 year-old group (t = 2.239, P < 0.05). Conclusion:For stroke inpatients accepting rehabilitation, it is necessary to supply dietary with suitable energy, enough carbohydrate, less fat, and sufficient protein, calcium, iron, vitamin A, vitamin B1, vitamin B2 and dietary fiber in the diet.
ABSTRACT
Objective:To observe the condition of obesity and dietary nutrition for stroke patients accepting rehabilitation. Methods:From November, 2015 to June, 2018, 115 inpatients were investigated their height, body mass, somatotype and dietary. They were divided into 18-49 year-old group (n = 41), 50-64 year-old group (n = 54) and ≥ 65 year-old group (n = 20). Results:The ratio of overweight/obesity and abdominal obesity were high in all the groups. There were significant differences in the overweight/obesity ratio among the three groups (χ2 = 6.978, P < 0.05), but not in abdominal obesity ratio (χ2 = 3.290, P > 0.05). Their intake of energy, carbohydrate, vitamin B1, vitamin B2, vitamin E, calcium, potassium, magnesium and selenium in all the groups was less than the recommendation (t > 2.548, P < 0.05), while the intake of cholesterol, iron, phosphorus and copper was more (t > 2.476, P < 0.05). The intake of protein and fat was more than the recommendation in the 18-49 year-old and the 50-64 year-old groups (t > 2.041, P < 0.05), and the intake of niacin was more than the recommendation in the 18-49 year-old group (t = 2.239, P < 0.05). Conclusion:For stroke inpatients accepting rehabilitation, it is necessary to supply dietary with suitable energy, enough carbohydrate, less fat, and sufficient protein, calcium, iron, vitamin A, vitamin B1, vitamin B2 and dietary fiber in the diet.
ABSTRACT
Objective:To investigate the body composition and the nutrition of diet of the stroke inpatients during rehabilitation. Methods:From November, 2015 to December, 2018, 100 stroke inpatients were sequentially recruited and measured the body composition, and the diets were investigated. The correlations among their body composition, dietary nutrition and rehabilitation time were analyzed. Results:The skeletal muscle mass was less than the target quantity (t = -2.605, P < 0.05), the percentage of skeletal muscle of upper limbs was less in the affected side than in the unaffected side (t = -1.984, P < 0.05). The body mass, body mass index, body fat percentage and abdominal obesity were all significantly higher than the target quantity (t > 10.715, P < 0.001). The daily intake of energy, carbohydrates, vitamin B1, vitamin B2, vitamin E, calcium, potassium, zinc, magnesium and selenium were lower than the recommendation (|t| > 4.427, P < 0.05), but the daily intake of protein, fat, cholesterol, niacin, iron, phosphorus and copper were higher (t > 2.122, P < 0.05). There were correlation between body composition index and dietary protein, fat and rehabilitation time (P < 0.05). Conclusion:It is necessary to reduce the fat intake and promote sufficient intake of carbohydrate, protein and so on, in nutritional intervention plans for hospitalized stroke rehabilitation patients.
ABSTRACT
Plate assay and spore germination method were used to study the chemotaxis response of Alternaria panax to arginine, glutamic acid, aspartic acid and threonine. The result showed that the optimum temperature of A. panax chemotaxis response to four amino acids were all 25 ℃. And chemotaxis responses of A. panax were different under conditions of different concentration and pH value. The chemotaxin reached to the highest under the condition of 2 mg•L⁻¹ and pH value was 7 for arginine, glutamic acid and threonine while 20 mg•L⁻¹ and pH value was 6 for aspartic acid . The data of chemotactic migration index (CMI) were 1.24, 1.38, 1.27, 1.31 and chemotactic growth rates(CGR) were 0.451 0, 0.353 0, 0.381 3, 0.228 8 and spores germination rates(SGR) were 57.33%，63%，56.67%，58% and the dry weight of mycelial (DWM) were 372.9, 348.5, 314.4, 390.2 mg•L⁻¹ respectively. It indicated that the low and middle concentration of amino acid had significant promoting effect on chemotaxis response of A. panax. As important substances generated in ginseng root, amino acids exhibited an efficient chemotactic effect on A. panax, and some even show inhibition effect under high concentration.
ABSTRACT
<p><b>OBJECTIVE</b>To explore the features of immunophenotypes and the characteristics of molecular biology and cellular genetics of AML patients with CD7 and CD4 expression.</p><p><b>METHODS</b>The immunophenotypical markers of AML cells were detected by multiple parameter flow cytometry; the expression of WT1, MDK, ETO, PML-RaRa and BCR-ABL were detected by RT-PCR; and cellular features were analyzed by R-band in 304 patients. The patients were divided into three groups according to their immunophenotypes: AML with CD7 expression (CD7 group), AML with CD4 expression(CD4 group) and AML without CD7 and CD4 expression (common AML group).</p><p><b>RESULTS</b>The expression rate and level of HLA-DR in CD7 group were higher than those in the common AML group, and the expression rate of CD33 and CD34 was higher than that in the other two groups. The expression rate and level of CD15, CD64 in the CD4 group were higher than those in the other 2 groups, and the expression rate and level of CD33 were higher than those in the common AML group. WT1 expression in the CD7 group was lower than that in the common AML group. PML-RaRa was not detected in the CD7 group. AML with co-expression of CD4 or CD7 showed more normal karyotype. (15;17) was not found in AML with CD7 expression.</p><p><b>CONCLUSION</b>AML cells with CD7 expression originate from precursor cells and are blocked in the early phase of hematological development; AML cells with CD4 expression originate from more mature stage of hematological devevelopment and with CD33, CD64 and CD15 high expression; AML cells with CD7 and CD4 expression are characterized by no-specific change of cellular genetics. According to the expression level and intesity of CD4 and CD7, and together with other specific lineage markers, the MRD in AML patients can be quantitatively detected.</p>
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the therapeutic efficacy of nonmyeloablative allogeneic hematopoietic stem cells transplantation for severe acquired aplastic anemia (SAA).</p><p><b>METHODS</b>Fourteen patients with severe acquired aplastic anemia received nonmyeloablative allogeneic hematopoietic stem cells transplantation from HLA matched sibling donors, among them 8 cases were dagnosed as SAA-I, 6 cases were diagnosed as SAA-II. The conditioning regimen consisted of fludarabine (FIUD), cyclophosphamide (CTX) and anti-thymocyte globulin (ATG/ALG). The prophylaxis for graft-versus-host disease (GVHD) was performed with cyclosporine (CsA) combined with mycophenolate mofetil (MMF) or tacrolimus (FK506).</p><p><b>RESULTS</b>All the patients gained a quick successfully engraftment of donor hametopoietic cells. The mean recovery time for neutrophil and platelet was 9 d and 13 d respectively. All the patients have acquired a full donor chimerism before 14 d. There were only 2 cases of GVHD: one out of them was acute skin GVHD (grade I) at day 70 after transplantation and the other was chronic liver GVHD (grade I) in 1 years after transplantation, the GVHD more than degree II did not coccur in all patients, 9 patients with bacterial and fungal mixed infection and (or) virus infection were observed, and improved after anti-infection therapy. The median follow-up time were 54.5 months (ranged between 5-144 months), and 12 patients remain disease-free survival currently, only 2 patients died of fungal infectin.</p><p><b>CONCLUSION</b>Transplantation of nonmyeloablative allogeneic hematopoietic stem cell is safe and effective for the treatment of severe acquired aplastic, but the prevention, treatment and monitoring of infection need to be enhance.</p>
Subject(s)
Humans , Allografts , Anemia, Aplastic , Antilymphocyte Serum , Cyclophosphamide , Cyclosporine , Disease-Free Survival , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells , Mycophenolic Acid , Neutrophils , Siblings , Tissue Donors , Transplantation Conditioning , VidarabineABSTRACT
Phosphatidylinositide 3-kinase (PI3K)/protein kinase B (PKB, Akt) pathway plays a major role in proliferation and survival of many types of cells. The inhibitory effect of LY294002, widely applied as an inhibitor of PI3K, in combination with gemcitabine on proliferation of PANC-1 cells was investigated. The expression of PI3K, phosphorylated Akt (p-Akt) and multidrug-resistance like protein (MRP) in normal pancreas tissues, chronic pancreatitis tissues and pancreatic carcinoma tissues was detected. The effects of LY294002 combined with gemcitabine on proliferation of PANC-1 cells and protein levels of p-Akt and MRP were detected. The results showed that the positive expression rate of PI3K, p-Akt and MRP in pancreatic carcinoma tissues was significantly higher than that in normal pancreas tissues and chronic pancreatitis tissues (P<0.01 and P<0.05 respectively). LY294002 could effectively enhance the inhibitory effect of gemcitabine on proliferation of PANC-1 cells. Furthermore, Western blotting revealed that LY294002 combined with gemcitabine reduced the protein levels of p-Akt and MRP, which contributed to the inhibition of proliferation. It is concluded that LY294002 in combination with gemcitabine may represent an alternative therapy for pancreatic carcinoma.
ABSTRACT
Phosphatidylinositide 3-kinase (PI3K)/protein kinase B (PKB, Akt) pathway plays a major role in proliferation and survival of many types of cells. The inhibitory effect of LY294002, widely applied as an inhibitor of PI3K, in combination with gemcitabine on proliferation of PANC-1 cells was investigated. The expression of PI3K, phosphorylated Akt (p-Akt) and multidrug-resistance like protein (MRP) in normal pancreas tissues, chronic pancreatitis tissues and pancreatic carcinoma tissues was detected. The effects of LY294002 combined with gemcitabine on proliferation of PANC-1 cells and protein levels of p-Akt and MRP were detected. The results showed that the positive expression rate of PI3K, p-Akt and MRP in pancreatic carcinoma tissues was significantly higher than that in normal pancreas tissues and chronic pancreatitis tissues (P<0.01 and P<0.05 respectively). LY294002 could effectively enhance the inhibitory effect of gemcitabine on proliferation of PANC-1 cells. Furthermore, Western blotting revealed that LY294002 combined with gemcitabine reduced the protein levels of p-Akt and MRP, which contributed to the inhibition of proliferation. It is concluded that LY294002 in combination with gemcitabine may represent an alternative therapy for pancreatic carcinoma.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Antimetabolites, Antineoplastic , Cell Proliferation , Chromones , Deoxycytidine , Dose-Response Relationship, Drug , Drug Synergism , Drug Therapy, Combination , Methods , Enzyme Inhibitors , Morpholines , Pancreatic Neoplasms , Drug Therapy , Pathology , Phosphatidylinositol 3-Kinases , Treatment Outcome , Tumor Cells, CulturedABSTRACT
This study was purposed to investigate the proliferation and antitumor activity of rhG-CSF-mobilized peripheral blood mononuclear cells (G-PBMNCs) activated by interleukin 21 (IL-21) alone or in combination with interleukin 15 (IL-15)/interleukin 2 (IL-2) and to evaluate the feasibility and value of tumor immunotherapy with cytokine combinations. G-PBMNCs were activated by IL-21 alone or in combination with IL-15/IL-2 in vitro, and the proliferation of the activated G-PBMNCs was analyzed by CCK-8 assay. The cytotoxicity of the activated G-PBMNC to the K562 cells was studied by the test principle which is based on target cell labeling with 5-(6)-carboxy-fluorescein succinimidyl ester (CFSE) and subsequent DNA-labeling with propidium iodide (PI) for identification of target cells with compromised cell membranes. The phenotypes of the activated G-PBMNCs were assayed by flow cytometry. The results showed that the cytotoxicity of IL-21 group had no difference from which of IL-2 group. When G-PBMNCs were exposed to the combinations of IL21+IL15/IL21+IL15+IL2, the cytotoxicity was significantly enhanced at E:T ratio of 25:1, as compared with combination of IL21+IL2 (p<0.05). The cytotoxicity of the cytokines combinations was significantly higher than that in cytokine used alone at E:T ratio of 50:1 (p<0.05). The cryopreservative and resuscitative G-PBMNCs showed the same result with the fresh G-PBMNCs in cytotoxicity test. The proportions of CD3+ and CD8+ T cells were increased when G-PBMNCs were incubated with cytokines for 72 hours. CD4, CD3-56+ and CD3+56+ counts were significantly elevated when G-PBMNCs were exposed to IL21 + IL15 (p<0.05). It is concluded that IL-21 alone enhance the antitumor activity of G-PBMNCs, which further strengthens when IL-21 combinated with IL-15.